Single-Centre/Open Label, 24 Weeks, Phase I Clinical Trial Of Ancilla Domini Gitu-Agonist Inverse Transcription Therapeutics On Gastro-Intestinal Tract Ulcers

Single-Centre/Open Label, 24 Weeks, Phase I Clinical Trial Of Ancilla Domini Gitu-Agonist CHoTA-GITU Inverse Transcription Therapeutics On Gastro-Intestinal Tract Ulcers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202410689792597

Enrollment

Registered

2024-10-09

Start date

2024-01-06

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System

Interventions

Ancilla Domini CHoTTA GITU

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adults 18+ years old 2. Male/Female 3. Residents in any part of Ghana 4. All nationalities/race 5. People diagnosed of GASTRIC/STOMACH ULCERS/HEARTBURNS.

Exclusion criteria

Exclusion criteria: 1. Children/under 18 years. 2. Pregnant/ Lactating Mothers.

Design outcomes

Primary

Measure	Time frame
Over 80% GIT Ulcers shall be cured/pains gone;Over 80% of enrollees with different forms of GIT Ulcers shall receive cure with almost no side effects (99.9% safety)	—

Secondary

Measure	Time frame
Over 80% GIT Ulcers research participants shall be cured with only CHoTA-GITU monotherapy;Ancilla Domini CHoTA -GITU shall cure all forms of Gastro-Intestinal Tract Ulcers in a very short period	—

Countries

Ghana

Contacts

Public ContactGeoffrey Alee

Public Relations Executive

denudation2015@gmail.com+2347041388422

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026